|Day Low/High||43.51 / 44.11|
|52 Wk Low/High||36.00 / 46.47|
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.
The narrative in the market is that we are waiting for the Fed decision on Wednesday -- but of course it's not that clear cut is it?
Stocks end moderately ahead as investors are adopting a cautious stance heading into this week's Federal Reserve meeting.
I'm inclined to add to Disney on today's weakness.
Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.
A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.
- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term
Larry Swedroe lays out the fundamental truths of investing -- for beginners.
Pfizer Inc. (NYSE:PFE) announced today positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA).
It was a great week for stocks, says Jim Cramer. And he's got your game plan for next week.
NEW ORLEANS, June 7, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Jim Cramer takes a look at PayPal, Tesla, Pfizer, Americold Realty Trust, Continental Resources, United Natural Foods, Cintas, Splunk and more.
Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman, Ph.
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #16 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Despite being ranked lower than the median among analyst picks of the Dow, Pfizer Inc ranks better than the median among analyst picks for the broader S&P 500 index components, claiming the #205 spot out of 500.
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA ® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary...
Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.